SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY

被引：5
|
作者：
Matucci-Cerinic, M. [1 ]
Schulze-Koops, H. [2 ]
Buch, M. [3 ]
Kavanaugh, A. [4 ]
Allanore, Y. [5 ]
Kucharz, E. J. [6 ]
Babic, G. [7 ]
机构：
[1] Univ Florence, Florence, Italy
[2] Ludwig Maximillans Univ, Munich, Germany
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Paris Descartes Univ, Cochin Hosp, Paris, France
[6] Med Univ Silesia, Katowice, Poland
[7] Hexal AG, Holzkirchen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0129
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [1] Phase 3 Equira 48 Week Study Results Demonstrated No Impact on Efficacy and Safety When Patients with Moderate-to-Severe Rheumatoid Arthritis Were Switched between Reference Etanercept (ETN) and GP2015, an Etanercept Biosimilar
    Kavanaugh, Arthur
    Matucci-Cerinic, Marco
    Schulze-Koops, Hendrik
    Buch, Maya
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
    Janusz Jaworski
    Marco Matucci-Cerinic
    Hendrik Schulze-Koops
    Maya H. Buch
    Eugeniusz J. Kucharz
    Yannick Allanore
    Arthur Kavanaugh
    Philip Young
    Goran Babic
    Arthritis Research & Therapy, 21
  • [3] Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
    Jaworski, Janusz
    Matucci-Cerinic, Marco
    Schulze-Koops, Hendrik
    Buch, Maya H.
    Kucharz, Eugeniusz J.
    Allanore, Yannick
    Kavanaugh, Arthur
    Young, Philip
    Babic, Goran
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [4] Etanercept Biosimilar GP2015 Has Equivalent Efficacy and Safety to Etanercept Originator in Patients with Moderate to Severe Rheumatoid Arthritis: The Phase 3 Equira Study
    Kavanaugh, Arthur
    Allanore, Yannick
    Kucharz, Eugeniusz J.
    Babic, Goran
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
    Matucci-Cerinic, Marco
    Allanore, Yannick
    Kavanaugh, Arthur
    Buch, Maya H.
    Schulze-Koops, Hendrik
    Kucharz, Eugeniusz J.
    Woehling, Heike
    Babic, Goran
    Poetzl, Johann
    Davis, Adanna
    Schwebig, Arnd
    RMD OPEN, 2018, 4 (02):
  • [6] EFFECTIVENESS AND SAFETY OF BIOSIMILAR ETANERCEPT GP2015 IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UK: RESULTS FROM THE COMPACT STUDY
    Askari, Ayman
    Both, Charlotte
    Martin, Angela
    Walsh, David A.
    Sheeran, Tom
    RHEUMATOLOGY, 2024, 63 : I81 - I81
  • [7] Effectiveness and safety of biosimilar etanercept GP2015 in patients with rheumatoid arthritis in the UK: results from the COMPACT study
    Askari, Ayman
    Both, Charlotte
    Martin, Angela
    Walsh, David A.
    Sheeran, Tom
    RHEUMATOLOGY, 2024, 63
  • [8] Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study
    Carballo, Nuria
    Perez Garcia, Carolina
    Grau, Santiago
    Monfort, Jordi
    Duran-Jorda, Xavier
    Echeverria-Esnal, Daniel
    Ferrandez, Olivia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study
    Wiland, Piotr
    Jeka, Slawomir
    Dokoupilova, Eva
    Brandt-Juergens, Jan
    Miranda Limon, Juan Manuel
    Cantalejo Moreira, Miguel
    Veiga Cabello, Raul
    Jauch-Lembach, Julia
    Thakur, Anjali
    Haliduola, Halimuniyazi
    Brueckmann, Ines
    Gaylis, Norman B.
    BIODRUGS, 2020, 34 (06) : 809 - 823
  • [10] Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
    Reich, Kristian
    Soung, Jennifer
    Gooderham, Melinda
    Zhang, Zuoshun
    Nograles, Kristine
    Day, Robert M.
    Ferris, Laura
    Goodfield, Mark
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345